Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 1/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566496 | 0.81 | MEN1 (0.33) | MAPK1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1566243 | 0.78 | MAPK1 (0.33) | OPRM1MAPK1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6513736 | 0.76 | LMNA (0.44) | MAPK1SMN1; SMN2LMNAPOLBGAA | |
| SCHEMBL24165561 | 0.72 | SLC6A12 (0.33) | SLC6A12SLC6A11 | |
| SCHEMBL1566652 | 0.70 | OPRM1 (0.40) | OPRM1SLC22A1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL17893420 | 0.69 | ALDH1A1 (0.46) | OPRM1SLC22A1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL24165529 | 0.69 | LMNA (0.37) | MAPK1LMNAPOLBCYP3A4CYP2D6 | |
| SCHEMBL7689091 | 0.69 | PSEN1 (0.38) | PPM1BPTPN1PPP1CCOPRM1SLC22A1 | |
| SCHEMBL10293983 | 0.69 | GRM4 (0.39) | SLC6A12SLC6A11LMNAPOLBCYP2D6 | |
| SCHEMBL19357068 | 0.68 | LMNA (0.49) | LMNAPOLBCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305684-A1 | Poycyloalkylpurines as adenosine receptor antagonists | Biogen Idec MA Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-7579354-B2 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2009-08-25 | — | — | US | disclosed |
| EP-2070930-A1 | Polycycloalkylpurines as adenosine receptor antagonists | Biogen Idec MA, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1230243-B1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1775297-A2 | Adenosine receptor antagonists and methods of making and using the same | Biogen Idec MA, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1230241-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2007-01-18 | — | — | US | disclosed |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | KIESMAN WILLIAM F | 2006-11-09 | — | — | US | disclosed |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ENSINGER CAROL L | 2005-10-06 | — | — | US | disclosed |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6649600-B1 | 2,6-Dioxo or dithioxy-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo derivatives; highly potent and selective diuretics | BIOGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| US-6605600-B1 | Diuretics | BIOGEN, INCORPORATED | 2003-08-12 | — | — | US | disclosed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1230243-A1 | POYCYLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034610-A1 | POLYCYCLOALKYLPURINES AS ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | SLC6A12 3619/4885SLC6A11 2642/4885PPM1B 3155/4885 |
| US-20090221821-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | SLC6A12 3619/4885SLC6A11 2642/4885PPM1B 3155/4885 |
| US-20060252730-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | SLC6A12 3619/4885SLC6A11 2642/4885PPM1B 3155/4885 |
| US-20070015732-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | SLC6A12 3619/4885SLC6A11 2642/4885PPM1B 3155/4885 |
| US-20040067966-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | SLC6A12 4021/4885SLC6A11 3039/4885PPM1B 2759/4885 |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | SLC6A12 4054/4885SLC6A11 3062/4885PPM1B 2908/4885 |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | SLC6A12 3619/4885SLC6A11 2642/4885PPM1B 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.